Valaciclovir for Epstein-Barr Virus Suppression in Moderate-to-Severe COPD

Linden, Dermot; Guo-Parke, Hong; McKelvey, Michael C; Einarsson, G; Lee, Andrew; Fairley, Derek; Brown, Vanessa; Lundy, Gavin; Campbell, Christina; Logan, Danielle; McFarland, Margaret; Singh, Dave; McAuley, Daniel F.; Taggart, Clifford C.; Kidney, Joseph C.

doi:10.1016/j.chest.2023.03.040

Cited by 5 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our patient there were initial concerns for hemophagocytic lymphohistiocytosis given the recognised role of EBV in precipitating similar reactions in other inborn errors of immunity. Valaciclovir is an inhibitor of EBV replication and has been suggested to be an adjunct therapy in the treatment of hemophagocytic lymphohistiocytosis and has been shown to inhibit viral shedding [ 16 – 18 ]. In our patient, a continuous reduction in quantitated levels of EBV without the addition of other immunomodulators was noted, with elimination of viraemia over 8 weeks.…”

Section: Discussionmentioning

confidence: 99%

Development of EBV Related Diffuse Large B-cell Lymphoma in Deficiency of Adenosine Deaminase 2 with Uncontrolled EBV Infection

Gardner,

Vaughan,

Avery

et al. 2024

J Clin Immunol

View full text Add to dashboard Cite

Deficiency of Adenosine Deaminase 2 (DADA2) patients presenting with primary immunodeficiency are at risk of uncontrolled EBV infection and secondary malignancies including EBV-related lymphoproliferative disorders (LPD). This paper describes the first case of EBV related diffuse large B-cell lymphoma in a patient with DADA2 and uncontrolled EBV infection. Consideration should be given to monitoring for EBV viraemia and to preventative EBV specific therapy in DADA2 and patients with at risk primary immunodeficiencies. A type I interferon (IFN) gene signature is associated with DADA2 though its association with immune dysregulation is unclear.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of EBV Related Diffuse Large B-cell Lymphoma in Deficiency of Adenosine Deaminase 2 with Uncontrolled EBV Infection

Gardner,

Vaughan,

Avery

et al. 2024

J Clin Immunol

View full text Add to dashboard Cite

show abstract

Antivirals for COPD?

Balfour

2023

CHEST

View full text Add to dashboard Cite

Effects of core training based on respiratory therapy on elderly stable COPD patients in the rehabilitation hospital: a study protocol for a randomised controlled trial

Su,

Qu,

Wei

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionElderly stable chronic obstructive pulmonary disease (COPD) patients frequently experience walking dysfunction. Research indicates that balance training holds promise for enhancing walking stability in these individuals, whereas respiratory therapy (RT) can enhance walking endurance effectively. However, existing balance training regimens tailored for COPD are intricate and lack specificity, and the impact of combined RT on patients’ walking function remains uncertain. This study aims to assess the influence of core training (CT) integrated with RT on walking function among elderly stable COPD patients.Methods and analysisThis randomised, assessment-blinded, routine rehabilitation-controlled trial will be carried out at the Department of Respiratory and Critical Care Rehabilitation, the Second Rehabilitation Hospital of Shanghai. A total of 42 elderly patients diagnosed with stable COPD will be randomly allocated to either the study group (SG) or the control group in a 1:1 ratio. Both groups will undergo 6 weeks of standard rehabilitation training. Additionally, patients in the SG will receive CT based on RT. The primary outcome of the study is the 6 min walk test. Secondary outcomes encompass ultrasound indicators of the diaphragm and multifidus, pulmonary function tests, Berg balance scale test, trunk impairment scale test, COPD assessment test and St. George’s Respiratory Questionnaire.Ethics and disseminationEthical approval was obtained from the Ethics Committee of the Second Rehabilitation Hospital of Shanghai (2023-01-01, see online supplemental file 1). All patients will provide written informed consent before participation. The results of the trial are intended for publication in a peer-reviewed journal.Trial registration numberChiCTR2400080276.

show abstract

Valaciclovir for Epstein-Barr Virus Suppression in Moderate-to-Severe COPD

Cited by 5 publications

References 37 publications

Development of EBV Related Diffuse Large B-cell Lymphoma in Deficiency of Adenosine Deaminase 2 with Uncontrolled EBV Infection

Development of EBV Related Diffuse Large B-cell Lymphoma in Deficiency of Adenosine Deaminase 2 with Uncontrolled EBV Infection

Antivirals for COPD?

Effects of core training based on respiratory therapy on elderly stable COPD patients in the rehabilitation hospital: a study protocol for a randomised controlled trial

Contact Info

Product

Resources

About